

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

October 20, 2022

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers,
Dalal Street, Mumbai-400001
Script Id: 506365

Subject: Outcome of Board Meeting Held on Thursday, October 20, 2022

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. October 20, 2022, approved the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2022 along with the Limited Review Report thereon.

We are enclosing herewith, a copy of the Un-Audited Financial Results for the quarter and half year ended September 30, 2022 along with the Limited Review Report thereon by auditor and cash flow statement and statement of assets and liabilities for the half year ended on 30th September, 2022.

The Meeting commenced at 04.00 p.m. and concluded at 04.55 p.m.

Thanking You.

Yours Faithfully,

For CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI
DIRECTOR
(DIN -03063364)



Sanjay Rane & Associates

CHARTERED ACCOUNTANTS

C-403, Marathon Next Gen. Innova,
Opp. Peninsula Corporate Park,
Off Ganpatrao Kadam Marg,
Lower Parel, Mumbai-400 013.

Phone : 49198585
Telefax : 49198521
Email : admin@ssrane.net
Website : www.ssraneandco.com

LIMITED REVIEW REPORT

To,

Board of Directors of Chemo Pharma Laboratories Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of **CHEMO PHARMA LABORATORIES LIMITED** for the quarter ended September 30, 2022 and year to date results for the three months period from July 01, 2022 to September 30, 2022 ("the Statement").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates
Chartered Accountants
Firm Reg. No. 121089W



CA. Abhijeet Deshmukh
Partner
Membership No. 129145



Date: 17th October, 2022
Place: Mumbai

UDIN: 22129145AZYLMN3689

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2022

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Half Year Ended		Year Ended
		30th Sept 2022	30th June 2022	30th Sept 2021	30th Sept 2022	30th Sept 2021	31st March 2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations	-	-	-	-	-	-
II	Other Income	5,901	(3,847)	1,896	2,054	2,986	7,889
III	Total Revenue (I + II)	5,901	(3,847)	1,896	2,054	2,986	7,889
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	311	445	365	756	718	1,731
	(5) Depreciation and Amortisation Expenses	33	33	91	66	91	189
	(6) Administrative and Other Expenses	234	683	321	916	747	2,320
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	578	1,160	777	1,738	1,556	4,240
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	5,323	(5,007)	1,119	316	1,430	3,649
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	5,323	(5,007)	1,119	316	1,430	3,649
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	5,323	(5,007)	1,119	316	1,430	3,649
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	631
	(2) Tax Adjustment Previous Year	(19)	-	-	(19)	-	-
	(3) Deffered Tax	-	-	-	-	-	(296)
	(4) MAT Credit Entitlement	-	-	-	-	-	(2,285)
XI	Profit/(Loss) for the period from continuing operations (IX - X)	5,341	(5,007)	1,119	334	1,430	5,599
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	5,341	(5,007)	1,119	334	1,430	5,599
XVI	Other Comprehensive Income						
	A (i) Itmes that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Itmes that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	5,341	(5,007)	1,119	334	1,430	5,599
XVIII	Earnings per Share :						
	(1) Basic	3.56	(3.34)	0.75	0.22	0.95	3.73
	(2) Diluted						

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2022 have been reviewed by the Audit Committee in their Meeting held on 20.10.2022 and approved by the Board of Directors of its Meeting held on 20.10.2022. The Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.



For Chemo Pharma Laboratories Limited

Ashok Somani

Director

DIN : 03063364

Date : 20th October, 2022

Place : Mumbai

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER, 2022

(Rupees in Thousand)

Sr. No.	PARTICULARS	As at 30.09.2022 Unaudited	As at 31.03.2022 Audited
1	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant & Equipment	326	391
	(b) Financial Assets		
	(i) Investment	34,284	29,442
	(ii) Loans	20,693	21,243
	(c) Deferred Tax Assets	2,581	2,581
	Total Non-Current Assets	57,883	53,656
2	Current Assets		
	(a) Financial Assets		
	(i) Cash & Cash Equivalents	851	6,859
	(ii) Bnk Balances other than (i) above	55,000	55,000
	(iii) Other Financial Assets	2,185	-
	(b) Current Tax Assets	1,023	1,114
	Total Current Assets	59,059	62,973
	TOTAL ASSETS	1,16,943	1,16,630
2	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	1,00,881	1,00,547
	Total Equity	1,15,881	1,15,547
2	Liabilities		
1	Non-Current Liabilities	-	-
2	Current Liabilities		
	(a) Financial Liabilities		
	(i) Other Financial Liabilities	431	52
	(b) Provisions	631	1,031
	Total Current Liabilities	1,062	1,083
	TOTAL EQUITY AND LIABILITIES	1,16,943	1,16,630

By Order of the Board

For Chemo - Pharma Laboratories Limited

Ashok Somani
Ashok Somani

Director

DIN : 03063364

Date : 20th October, 2022

Place : Mumbai



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE CASH FLOW STATEMENT FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER 2022

(Rupees in Thousand)

PARTICULARS	Half Year Ended 30.09.2022 Unaudited	Year Ended 31.03.2022 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and extraordinary items	316	3,649
Adjustement for		
Depreciation	66	189
Dividend received	(38)	(1,965)
Interest received	(2,173)	(4,746)
Operating profit before working capital changes	(1,830)	(2,872)
Adjustement for		
Increase (Decrease) in other Current Liabilities	(21)	498
Decrease (increase) in Current Assets	(2,094)	(222)
Purchase of Property, Plant and Equipments	-	(59)
Cash Generated From Operation	(2,115)	217
Taxes Paid	-	(631)
A. Cash Flow From Operating Activities	(3,945)	(3,286)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Dividend received	38	1,965
Interest received	2,173	4,746
Purchase / (Sale) of Investment	(4,842)	(29,034)
(Invetsment) / Proceeds from Maturity of Fixed Deposits (net)	-	32,000
Cash Flow From Investing Activities	(2,631)	9,677
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from ICD Re-paid / (Given)	550	(21,243)
Cash Flow From Financing Activities	550	(21,243)
Net increase/(decrease) in cash and cash Equivalents	(6,026)	(14,852)
Opening balance of Cash and Cash Equivalents	6,859	21,711
Closing Balance Of Cash and Cash Equivalents	833	6,859

For Chemo Pharma Laboratories Limited

Ashok Somani

Ashok Somani

Director

DIN : 03063364

Date : 20th October, 2022

Place : Mumbai



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2022

(Rupees in Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			UNAUDITED HALF YEAR ENDED		AUDITED YEAR ENDED
	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	578	(84)	1,119	492	1,430	5,599
Benefit / (Charge):	-	-	-	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	4,765	(4,923)	-	(158)	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
Net Profit / (Loss) for the Period (as per AS)	5,341	(5,007)	1,119	334	1,430	5,599

For Chemo Pharma Laboratories Limited



Ashok Somani

Ashok Somani
Director
DIN : 03063364

Date: 20th October, 2022
Place: Mumbai